206 related articles for article (PubMed ID: 21078112)
1. Therapeutic molecular targets in human chondrosarcoma.
Jamil N; Howie S; Salter DM
Int J Exp Pathol; 2010 Oct; 91(5):387-93. PubMed ID: 21078112
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163019
[TBL] [Abstract][Full Text] [Related]
3. The clinical management of chondrosarcoma.
Riedel RF; Larrier N; Dodd L; Kirsch D; Martinez S; Brigman BE
Curr Treat Options Oncol; 2009 Apr; 10(1-2):94-106. PubMed ID: 19238552
[TBL] [Abstract][Full Text] [Related]
4. Combined radiotherapy and razoxane in the treatment of chondrosarcomas and chordomas.
Rhomberg W; Eiter H; Böhler F; Dertinger S
Anticancer Res; 2006; 26(3B):2407-11. PubMed ID: 16821624
[TBL] [Abstract][Full Text] [Related]
5. Chondrosarcoma of the uterus.
Uchikova E; Uchikov A; Markova D
Acta Obstet Gynecol Scand; 2004 Jul; 83(7):686-7. PubMed ID: 15225197
[No Abstract] [Full Text] [Related]
6. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells.
Kim DW; Seo SW; Cho SK; Chang SS; Lee HW; Lee SE; Block JA; Hei TK; Lee FY
J Orthop Res; 2007 Jun; 25(6):820-8. PubMed ID: 17343283
[TBL] [Abstract][Full Text] [Related]
7. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.
Monderer D; Luseau A; Bellec A; David E; Ponsolle S; Saiagh S; Bercegeay S; Piloquet P; Denis MG; Lodé L; Rédini F; Biger M; Heymann D; Heymann MF; Le Bot R; Gouin F; Blanchard F
Lab Invest; 2013 Oct; 93(10):1100-14. PubMed ID: 23958880
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy of chondrosarcoma of bone.
Harwood AR; Krajbich JI; Fornasier VL
Cancer; 1980 Jun; 45(11):2769-77. PubMed ID: 7379008
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR.
Zhu Z; Wang CP; Zhang YF; Nie L
Asian Pac J Cancer Prev; 2014; 15(2):917-23. PubMed ID: 24568519
[TBL] [Abstract][Full Text] [Related]
10. Pathology of primary malignant bone and cartilage tumours.
Rozeman LB; Cleton-Jansen AM; Hogendoorn PC
Int Orthop; 2006 Dec; 30(6):437-44. PubMed ID: 16944143
[TBL] [Abstract][Full Text] [Related]
11. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
[TBL] [Abstract][Full Text] [Related]
12. A novel benzofuran derivative, ACDB, induces apoptosis of human chondrosarcoma cells through mitochondrial dysfunction and endoplasmic reticulum stress.
Su CM; Chen CY; Lu T; Sun Y; Li W; Huang YL; Tsai CH; Chang CS; Tang CH
Oncotarget; 2016 Dec; 7(50):83530-83543. PubMed ID: 27835579
[TBL] [Abstract][Full Text] [Related]
13. Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma.
Roche ME; Lin Z; Whitaker-Menezes D; Zhan T; Szuhai K; Bovee JVMG; Abraham JA; Jiang W; Martinez-Outschoorn U; Basu-Mallick A
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165962. PubMed ID: 32920118
[TBL] [Abstract][Full Text] [Related]
14. Trichodermin induces cell apoptosis through mitochondrial dysfunction and endoplasmic reticulum stress in human chondrosarcoma cells.
Su CM; Wang SW; Lee TH; Tzeng WP; Hsiao CJ; Liu SC; Tang CH
Toxicol Appl Pharmacol; 2013 Oct; 272(2):335-44. PubMed ID: 23806212
[TBL] [Abstract][Full Text] [Related]
15. Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets.
Nazeri E; Gouran Savadkoohi M; Majidzadeh-A K; Esmaeili R
Crit Rev Oncol Hematol; 2018 Nov; 131():102-109. PubMed ID: 30293700
[TBL] [Abstract][Full Text] [Related]
16. The oncogene LRF is a survival factor in chondrosarcoma and contributes to tumor malignancy and drug resistance.
Kumari R; Li H; Haudenschild DR; Fierro F; Carlson CS; Overn P; Gupta L; Gupta K; Nolta J; Yik JH; Di Cesare PE
Carcinogenesis; 2012 Nov; 33(11):2076-83. PubMed ID: 22847180
[TBL] [Abstract][Full Text] [Related]
17. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
Speetjens FM; de Jong Y; Gelderblom H; Bovée JV
Curr Opin Oncol; 2016 Jul; 28(4):314-22. PubMed ID: 27166664
[TBL] [Abstract][Full Text] [Related]
18. [Inflammation as molecular target in chondrosarcoma].
Kalinski T
Pathologe; 2014 Nov; 35 Suppl 2():249-53. PubMed ID: 25394974
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2/M arrest and apoptosis as well as autophagy.
Jiao G; Ren T; Guo W; Ren C; Yang K
Tumour Biol; 2015 May; 36(5):3969-77. PubMed ID: 25577250
[TBL] [Abstract][Full Text] [Related]
20. A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression.
Kim H; Cho Y; Kim HS; Kang D; Cheon D; Kim YJ; Chang MJ; Lee KM; Chang CB; Kang SB; Kang HG; Kim JH
Nat Commun; 2020 Oct; 11(1):5023. PubMed ID: 33024108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
